Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NorgesGruppen is Norway's leading grocery retail and wholesale conglomerate, controlling approximately 44% of the nation's grocery market through prominent chains such as KIWI, MENY, and SPAR. In a landmark expansion into the healthcare sector, the company completed the acquisition of Norsk Medisinaldepot (NMD) from McKesson Corporation in early 2026, incorporating the major pharmacy chains Vitusapotek and Ditt Apotek into its portfolio. This acquisition positions NorgesGruppen as a dominant player in pharmaceutical distribution and pharmacy retail, controlling roughly one-third of the Norwegian pharmacy market. While the group’s core business remains food retail and logistics through its subsidiary ASKO, its new healthcare division oversees the wholesale of medicines and the production of own-brand pharmaceutical products. Headquartered in Oslo and primarily owned by the Johannson family, NorgesGruppen is a cornerstone of the Norwegian consumer economy and a key infrastructure provider for medical supplies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NorgesGruppen.